dr. bradley on impact of spartan and prosper in nonmetastatic crpc
Published 5 years ago • 119 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
0:18
copy of dr. bradley on impact of spartan and prosper in nonmetastatic crpc
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
4:53
apalutamide: a next-gen agent for nonmetastatic crpc
-
0:39
copy of dr. bradley on next steps for research in nonmetastatic prostate cancer
-
1:32
dr. bradley on next steps for research in nonmetastatic prostate cancer
-
1:31
spartan vs. prosper: apalutamide or enzalutamide for nmcrpc?
-
7:00
comparing the second generation hormone therapies | ask a prostate expert, mark scholz, md
-
22:16
understanding non metastatic castration resistant prostate cancer with dr. hamilton
-
53:21
an interview with matthew r smith, md, phd — management of prostate cancer
-
0:57
dr. dorff on choosing between therapies in nonmetastatic crpc
-
21:25
an update on the prosper trial: focusing on nonmetastatic crpc
-
2:00
dr. shore on the tolerability of darolutamide in nonmetastatic crpc
-
0:44
dr. wise on the fda approval of apalutamide in non-metastatic crpc
-
1:06
dr. bradley on adverse events associated with enzalutamide and apalutamide in prostate cancer
-
1:10
dr. gomella on the fda approval of apalutamide for nonmetastatic crpc
-
2:32
dr. saad on the spartan trial in m0crpc
-
1:19
nonmetastatic crpc: meeting an unmet need
-
1:54
dr. plimack discusses trials investigating apalutamide, enzalutamide in m0 crpc
-
5:55
the future of treatment for nonmetastatic crpc
-
1:45
dr. choudhury on antiandrogen treatment selection in nonmetastatic crpc
-
0:51
dr. gomella on the fda approval of enzalutamide in nonmetastatic crpc
-
6:51
understanding nonmetastatic crpc: an overview